

## Special Issue

# Exploring Cutaneous Autoimmune Disease Flares in the Wake of COVID-19 Infection and Vaccination

### Message from the Guest Editors

Skin-related complications linked to COVID-19 infection and vaccination have been observed during the pandemic. These complications include the worsening of inflammatory dermatoses like psoriasis and the reactivation of skin infections such as herpes zoster. The exact mechanism of these flares and skin manifestations is not yet fully understood. Molecular mimicry and immune cross-reaction are thought to be the triggers of hyperinflammation, leading to the induction of innate and adaptive immune responses that result in a flare. This Special Issue aims at elucidating the factors associated with cutaneous autoimmune disease post COVID-19 infection and vaccination. Topics of interest include novel insights into these flares, comparative studies elucidating distinctions and similarities in immune responses between them, and therapeutic interventions and outcomes. Long-term follow-up observations are also of interest.

### Guest Editors

Prof. Dr. Angeliki-Victoria Roussaki-Schulze

Dr. Efterpi Zafiriou

Dr. Emmanouil Karampinis

### Deadline for manuscript submissions

10 May 2026



## Vaccines

an Open Access Journal  
by MDPI

Impact Factor 3.4  
CiteScore 9.9  
Indexed in PubMed



[mdpi.com/si/200369](https://mdpi.com/si/200369)

*Vaccines*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[vaccines@mdpi.com](mailto:vaccines@mdpi.com)

[mdpi.com/journal/  
vaccines](https://mdpi.com/journal/vaccines)





# Vaccines

---

an Open Access Journal  
by MDPI

---

Impact Factor 3.4  
CiteScore 9.9  
Indexed in PubMed



[mdpi.com/journal/  
vaccines](https://mdpi.com/journal/vaccines)



## About the Journal

### Message from the Editor-in-Chief

*Vaccines* (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

---

### Editor-in-Chief

Prof. Dr. Ralph A. Tripp

Department of Infectious Diseases, College of Veterinary Medicine,  
University of Georgia, Athens, GA 30602-7387, USA

---

### Author Benefits

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPIus / SciFinder, and other databases.

#### Journal Rank:

JCR - Q2 (Medicine, Research and Experimental) /  
CiteScore - Q1 (Pharmacology (medical))

#### Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 19.6 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the first half of 2025).